uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q15.1431 | Q15 | When was Indomethacin approved by the FDA? | The drug Indomethacin was first FDA approved for use in 1965. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_string) LIKE "%indomethacin%" OR LOWER(drugSynonyms_string) LIKE "%indomethacin%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3165', 'drugName': 'Indomethacin', 'tradeNames_string': 'Artracin, Artracin sr, Berlind 75 ret, Flexin-25 continus, Flexin-50 continus, Flexin-75 continus, Imbrilon, Indo-lemmon, Indo-paed, Indocid ret, Indocid-r, Indocin, Indocin sr, Indoderm, Indoflex, Indolar, Indolar sr, Indomax-25, Indomax-75 sr, Indomethacin, Indomod, Indoptol, Indotard mr 75, Ledmecin, Maximet sr, Mobilan, Pardelprin mr, Rheumacin la, Rimacid, Slo-indo, Tivorbex', 'drugSynonyms_string': 'Aconip, Durametacin, Indometacin, Indometacin farnesil, Indometacinum, Indomethacin, NSC-757061, NSC-77541, Reumacide', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4252', 'drugName': 'Indomethacin Sodium', 'tradeNames_string': 'Indocin, Indomethacin sodium', 'drugSynonyms_string': 'Indometacin sodium, Indometacin sodium hydrate, Indometacin sodium trihydrate, Indomethacin sodium, Indomethacin sodium anhydrous, Indomethacin sodium salt trihydrate, Indomethacin sodium trihydrate, Sodium indomethacin, Sodium indomethacin trihydrate', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1137 | Q15 | When was Fluvastatin approved by the FDA? | The drug Fluvastatin was first FDA approved for use in 1993. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluvastatin%" OR LOWER(tradeNames_string) LIKE "%fluvastatin%" OR LOWER(drugSynonyms_string) LIKE "%fluvastatin%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1307', 'drugName': 'Fluvastatin', 'tradeNames_string': '', 'drugSynonyms_string': 'Fluvas, Fluvastatin, NSC-758896', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1184', 'drugName': 'Fluvastatin Sodium', 'tradeNames_string': 'Dorisin xl, Fluvastatin sodium, Lescol, Lescol xl, Luvinsta xl, Nandovar xl, Pinmactil, Stefluvin xl', 'drugSynonyms_string': 'Almastatin, Canef, Cranoc, Fluindostatin, Fluvastatin sodium, Fluvastatin sodium salt, Fractal, Lipaxan, Lochol, Locol, Primexin, Vastin, XU 62-320, XU-62-320', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.791 | Q15 | When was Fosnetupitant Chloride Hydrochloride approved by the FDA? | The drug Fosnetupitant Chloride Hydrochloride was first FDA approved for use in 2018. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosnetupitant chloride hydrochloride%" OR LOWER(tradeNames_string) LIKE "%fosnetupitant chloride hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%fosnetupitant chloride hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4376', 'drugName': 'Fosnetupitant Chloride Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': '08-PNET, Fosnetupitant chloride, Fosnetupitant chloride hydrochloride, Fosnetupitant dihydrochloride', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1744 | Q15 | When was Adriforant approved by the FDA? | The drug Adriforant has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%adriforant%" OR LOWER(tradeNames_string) LIKE "%adriforant%" OR LOWER(drugSynonyms_string) LIKE "%adriforant%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.495 | Q15 | When was Hydrocortisone Hemisuccinate approved by the FDA? | The drug Hydrocortisone Hemisuccinate was first FDA approved for use in 1955. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrocortisone hemisuccinate%" OR LOWER(tradeNames_string) LIKE "%hydrocortisone hemisuccinate%" OR LOWER(drugSynonyms_string) LIKE "%hydrocortisone hemisuccinate%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1752', 'drugName': 'Hydrocortisone Hemisuccinate', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydrocortisone Hemisuccinate, Hydrocortisone succinate, NSC-757049, NSC-7576', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.157 | Q15 | When was Rosiglitazone approved by the FDA? | The drug Rosiglitazone was first FDA approved for use in 1999. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rosiglitazone%" OR LOWER(tradeNames_string) LIKE "%rosiglitazone%" OR LOWER(drugSynonyms_string) LIKE "%rosiglitazone%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4628', 'drugName': 'Rosiglitazone Maleate', 'tradeNames_string': 'Avandia, Rosiglitazone maleate', 'drugSynonyms_string': 'Avandia, BRL-49653, BRL-49653-C, BRL-49653C, NSC-717764, Rosiglitazone maleate, Rosiglitzazone maleate', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6144', 'drugName': 'Rosiglitazone', 'tradeNames_string': 'Avandia', 'drugSynonyms_string': 'Avandamet, Avandaryl, Avandia, BRL-49653, Gaudil, NSC-758698, Rezult, Rosiglitazone, Rosiglizole, Rosvel, TDZ-01', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.970 | Q15 | When was Netupitant approved by the FDA? | The drug Netupitant was first FDA approved for use in 2014. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%netupitant%" OR LOWER(tradeNames_string) LIKE "%netupitant%" OR LOWER(drugSynonyms_string) LIKE "%netupitant%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1207', 'drugName': 'Netupitant', 'tradeNames_string': '', 'drugSynonyms_string': 'Netupitant, RO 67-3189/000, RO-67-3189, RO-673189000', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1941', 'drugName': 'Fosnetupitant', 'tradeNames_string': '', 'drugSynonyms_string': '07-PNET, Fosnetupitant', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4376', 'drugName': 'Fosnetupitant Chloride Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': '08-PNET, Fosnetupitant chloride, Fosnetupitant chloride hydrochloride, Fosnetupitant dihydrochloride', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.860 | Q15 | When was Darusentan approved by the FDA? | The drug Darusentan has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%darusentan%" OR LOWER(tradeNames_string) LIKE "%darusentan%" OR LOWER(drugSynonyms_string) LIKE "%darusentan%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1325 | Q15 | When was Crisaborole approved by the FDA? | The drug Crisaborole was first FDA approved for use in 2016. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%crisaborole%" OR LOWER(tradeNames_string) LIKE "%crisaborole%" OR LOWER(drugSynonyms_string) LIKE "%crisaborole%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5927', 'drugName': 'Crisaborole', 'tradeNames_string': 'Eucrisa', 'drugSynonyms_string': 'AN-2728, AN2728, Crisaborole', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.632 | Q15 | When was Difamilast approved by the FDA? | The drug Difamilast has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%difamilast%" OR LOWER(tradeNames_string) LIKE "%difamilast%" OR LOWER(drugSynonyms_string) LIKE "%difamilast%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.692 | Q15 | When was Eltrombopag approved by the FDA? | The drug Eltrombopag was first FDA approved for use in 2008. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eltrombopag%" OR LOWER(tradeNames_string) LIKE "%eltrombopag%" OR LOWER(drugSynonyms_string) LIKE "%eltrombopag%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2769', 'drugName': 'Eltrombopag Olamine', 'tradeNames_string': 'Promacta, Promacta kit', 'drugSynonyms_string': 'Eltrombopag (as olamine), Eltrombopag compd with 2-aminoethanol (1:2), Eltrombopag olamine, SB-497115-GR', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1104', 'drugName': 'Eltrombopag', 'tradeNames_string': 'Revolade', 'drugSynonyms_string': 'Eltrombopag, SB497115', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1562 | Q15 | When was Olopatadine approved by the FDA? | The drug Olopatadine was first FDA approved for use in 1996. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olopatadine%" OR LOWER(tradeNames_string) LIKE "%olopatadine%" OR LOWER(drugSynonyms_string) LIKE "%olopatadine%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6184', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_string': 'Olopatadine hydrochloride, Pataday, Pataday once daily relief, Pataday twice daily relief, Patanase, Patanol, Pazeo', 'drugSynonyms_string': 'ALO-4943A, ALO4943A, Allelock, KW-4679, KW4679, Olopatadine (as hydrochloride), Olopatadine hcl, Olopatadine hydrochloride', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4800', 'drugName': 'Olopatadine', 'tradeNames_string': 'Opatanol', 'drugSynonyms_string': 'AL-4943A, Olopatadine', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.575 | Q15 | When was Phenoxybenzamine Hydrochloride approved by the FDA? | The drug Phenoxybenzamine Hydrochloride was first FDA approved for use in 1953. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenoxybenzamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%phenoxybenzamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%phenoxybenzamine hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1879', 'drugName': 'Phenoxybenzamine Hydrochloride', 'tradeNames_string': 'Dibenyline, Dibenzyline, Phenoxybenzamine hydrochloride', 'drugSynonyms_string': 'Bensylyte hydrochloride, Dibenzylin, Dibenzyline chloride, Dibenzyline hydrochloride, Dibenzyran, NSC-37448, Phenoxybenzamine chloride, Phenoxybenzamine hcl, Phenoxybenzamine hydrochloride', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1909 | Q15 | When was Chlorzoxazone approved by the FDA? | The drug Chlorzoxazone was first FDA approved for use in 1958. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlorzoxazone%" OR LOWER(tradeNames_string) LIKE "%chlorzoxazone%" OR LOWER(drugSynonyms_string) LIKE "%chlorzoxazone%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_326', 'drugName': 'Chlorzoxazone', 'tradeNames_string': 'Chlorzoxazone, Paraflex, Parafon, Parafon Forte, Parafon forte dsc, Parafon-Forte, Strifon, Strifon forte dsc', 'drugSynonyms_string': 'Chlorzoxazone, NSC-26189', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.18 | Q15 | When was Futibatinib approved by the FDA? | The drug Futibatinib was first FDA approved for use in 2022. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%futibatinib%" OR LOWER(tradeNames_string) LIKE "%futibatinib%" OR LOWER(drugSynonyms_string) LIKE "%futibatinib%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6327', 'drugName': 'Futibatinib', 'tradeNames_string': 'Lytgobi', 'drugSynonyms_string': 'Fgfr-in-1, Futibatinib, TAS-120, Tas 120, Tas-120', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.130 | Q15 | When was Olopatadine Hydrochloride approved by the FDA? | The drug Olopatadine Hydrochloride was first FDA approved for use in 1996. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olopatadine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%olopatadine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%olopatadine hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6184', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_string': 'Olopatadine hydrochloride, Pataday, Pataday once daily relief, Pataday twice daily relief, Patanase, Patanol, Pazeo', 'drugSynonyms_string': 'ALO-4943A, ALO4943A, Allelock, KW-4679, KW4679, Olopatadine (as hydrochloride), Olopatadine hcl, Olopatadine hydrochloride', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1361 | Q15 | When was Pregabalin approved by the FDA? | The drug Pregabalin was first FDA approved for use in 2004. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pregabalin%" OR LOWER(tradeNames_string) LIKE "%pregabalin%" OR LOWER(drugSynonyms_string) LIKE "%pregabalin%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2991', 'drugName': 'Pregabalin', 'tradeNames_string': 'Alzain, Axalid, Lecaent, Lyrica, Lyrica cr, Pregabalin, Rewisca', 'drugSynonyms_string': 'CI-1008, NSC-759256, PD-144723, Pregabalin, Pregabalin mylan, Pregabalin sandoz, Pregabalin sandoz gmbh, Pregabalin zentiva, Vronogabic, YNP-1807', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1291 | Q15 | When was Biciromab Brallobarbital approved by the FDA? | The drug Biciromab Brallobarbital has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%biciromab brallobarbital%" OR LOWER(tradeNames_string) LIKE "%biciromab brallobarbital%" OR LOWER(drugSynonyms_string) LIKE "%biciromab brallobarbital%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1969 | Q15 | When was Isopropamide Iodide approved by the FDA? | The drug Isopropamide Iodide was first FDA approved for use in 1957. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isopropamide iodide%" OR LOWER(tradeNames_string) LIKE "%isopropamide iodide%" OR LOWER(drugSynonyms_string) LIKE "%isopropamide iodide%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4390', 'drugName': 'Isopropamide Iodide', 'tradeNames_string': 'Darbid', 'drugSynonyms_string': 'Dipramid, Dipramide, Isamid, Isopropamide (as iodide), Isopropamide iodide, Isoproponum iodide, Marygin-m, NSC-15521, Piaccamide, Priamide, Priazimide, SKF-4740, Sanulcin, Tyrimide', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4391', 'drugName': 'Isopropamide Iodide', 'tradeNames_string': 'Darbid', 'drugSynonyms_string': 'Dipramid, Dipramide, Isamid, Isopropamide (as iodide), Isopropamide iodide, Isoproponum iodide, Marygin-m, NSC-15521, Piaccamide, Priamide, Priazimide, SKF-4740, Sanulcin, Tyrimide', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.935 | Q15 | When was Apremilast approved by the FDA? | The drug Apremilast was first FDA approved for use in 2014. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%apremilast%" OR LOWER(tradeNames_string) LIKE "%apremilast%" OR LOWER(drugSynonyms_string) LIKE "%apremilast%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2487', 'drugName': 'Apremilast', 'tradeNames_string': 'Otezla', 'drugSynonyms_string': 'Apremilast, CC-10004, CC10004', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.989 | Q15 | When was Eprosartan approved by the FDA? | The drug Eprosartan was first FDA approved for use in 1997. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eprosartan%" OR LOWER(tradeNames_string) LIKE "%eprosartan%" OR LOWER(drugSynonyms_string) LIKE "%eprosartan%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5954', 'drugName': 'Eprosartan', 'tradeNames_string': 'Teveten', 'drugSynonyms_string': 'Eprosartan, SK&F 108566, SK&F-108566, SK-108566, Teveten', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5528', 'drugName': 'Eprosartan Mesylate', 'tradeNames_string': 'Eprosartan mesylate, Teveten', 'drugSynonyms_string': 'Eprosartan mesilate, Eprosartan mesylate, Eprosartan monomethanesulfonate, SK&F 108566-J, SK&F-108566-J', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1965 | Q15 | When was Meprednisone approved by the FDA? | The drug Meprednisone was first FDA approved for use in 1982. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%meprednisone%" OR LOWER(tradeNames_string) LIKE "%meprednisone%" OR LOWER(drugSynonyms_string) LIKE "%meprednisone%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5378', 'drugName': 'Meprednisone', 'tradeNames_string': 'Betapar', 'drugSynonyms_string': 'Meprednisone, NSC-527579, SCH 4358, SCH-4358', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.193 | Q15 | When was Nefazodone Hydrochloride approved by the FDA? | The drug Nefazodone Hydrochloride was first FDA approved for use in 1994. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nefazodone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%nefazodone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%nefazodone hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5045', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugSynonyms_string': 'BMY 13754, BMY-13754, MJ 13,754-1, MJ-13754-1, NSC-760344, Nefazodone hcl, Nefazodone hydrochloride', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5046', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugSynonyms_string': 'BMY 13754, BMY-13754, MJ 13,754-1, MJ-13754-1, NSC-760344, Nefazodone hcl, Nefazodone hydrochloride', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5047', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugSynonyms_string': 'BMY 13754, BMY-13754, MJ 13,754-1, MJ-13754-1, NSC-760344, Nefazodone hcl, Nefazodone hydrochloride', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5048', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugSynonyms_string': 'BMY 13754, BMY-13754, MJ 13,754-1, MJ-13754-1, NSC-760344, Nefazodone hcl, Nefazodone hydrochloride', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1149 | Q15 | When was Febuxostat approved by the FDA? | The drug Febuxostat was first FDA approved for use in 2009. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%febuxostat%" OR LOWER(tradeNames_string) LIKE "%febuxostat%" OR LOWER(drugSynonyms_string) LIKE "%febuxostat%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1230', 'drugName': 'Febuxostat', 'tradeNames_string': 'Adenuric, Uloric', 'drugSynonyms_string': 'Febuxostat, NSC-758874, TMX-67', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1001 | Q15 | When was Sildenafil approved by the FDA? | The drug Sildenafil was first FDA approved for use in 1998. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sildenafil%" OR LOWER(tradeNames_string) LIKE "%sildenafil%" OR LOWER(drugSynonyms_string) LIKE "%sildenafil%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4134', 'drugName': 'Sildenafil Citrate', 'tradeNames_string': 'Revatio, Sildenafil citrate, Viagra', 'drugSynonyms_string': 'NSC-744009, NSC-758669, Sildenafil (as citrate), Sildenafil citrate, UK-92,480-10, UK-92480-10', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5817', 'drugName': 'Sildenafil', 'tradeNames_string': 'Nipatra, Revatio, Viagra, Vizarsin', 'drugSynonyms_string': 'Aphrodil, HIP-0908, HIP0908, Patrex, Sildenafil, Sildenafil actavis, Sildenafil ratiopharm, Sildenafil teva, UK-92480', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1956 | Q15 | When was Pentazocine approved by the FDA? | The drug Pentazocine was first FDA approved for use in 1967. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentazocine%" OR LOWER(tradeNames_string) LIKE "%pentazocine%" OR LOWER(drugSynonyms_string) LIKE "%pentazocine%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1542', 'drugName': 'Pentazocine', 'tradeNames_string': 'Fortral, Talwin', 'drugSynonyms_string': 'Dl-pentazocine, NIH-7958, NSC-107430, Pentazocine, Pentazocine civ, WIN 20,228, WIN-20228', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_652', 'drugName': 'Pentazocine Lactate', 'tradeNames_string': 'Talwin', 'drugSynonyms_string': 'Pentazocine lactate, Talwin (lactate)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3200', 'drugName': 'Pentazocine Hydrochloride', 'tradeNames_string': 'Sosegon, Talwin, Talwin 50', 'drugSynonyms_string': 'Pentazocine hcl, Pentazocine hydrochloride', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1657 | Q15 | When was Olanzapine approved by the FDA? | The drug Olanzapine was first FDA approved for use in 1996. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olanzapine%" OR LOWER(tradeNames_string) LIKE "%olanzapine%" OR LOWER(drugSynonyms_string) LIKE "%olanzapine%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2613', 'drugName': 'Olanzapine', 'tradeNames_string': 'Arkolamyl, Olanzapine, Zalasta, Zyprexa, Zyprexa zydis', 'drugSynonyms_string': 'LY-170053, LY170053, Olansek, Olanzapine, Olanzapine apotex, Olanzapine cipla, Olanzapine glenmark, Olanzapine mylan, Olanzapine teva, Olazax, Olazax disperzi, Zyprexa velotab', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2614', 'drugName': 'Olanzapine', 'tradeNames_string': 'Arkolamyl, Olanzapine, Zalasta, Zyprexa, Zyprexa zydis', 'drugSynonyms_string': 'LY-170053, LY170053, Olansek, Olanzapine, Olanzapine apotex, Olanzapine cipla, Olanzapine glenmark, Olanzapine mylan, Olanzapine teva, Olazax, Olazax disperzi, Zyprexa velotab', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2615', 'drugName': 'Olanzapine', 'tradeNames_string': 'Arkolamyl, Olanzapine, Zalasta, Zyprexa, Zyprexa zydis', 'drugSynonyms_string': 'LY-170053, LY170053, Olansek, Olanzapine, Olanzapine apotex, Olanzapine cipla, Olanzapine glenmark, Olanzapine mylan, Olanzapine teva, Olazax, Olazax disperzi, Zyprexa velotab', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1529', 'drugName': 'Olanzapine Pamoate', 'tradeNames_string': 'Zyprexa relprevv', 'drugSynonyms_string': 'Olanzapine (as embonate), Olanzapine embonate, Olanzapine pamoate, Olanzapine pamoate anhydrous, Olanzapine pamoate monohydrate, Zypadhera', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1530', 'drugName': 'Olanzapine Pamoate', 'tradeNames_string': 'Zyprexa relprevv', 'drugSynonyms_string': 'Olanzapine (as embonate), Olanzapine embonate, Olanzapine pamoate, Olanzapine pamoate anhydrous, Olanzapine pamoate monohydrate, Zypadhera', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1531', 'drugName': 'Olanzapine Pamoate', 'tradeNames_string': 'Zyprexa relprevv', 'drugSynonyms_string': 'Olanzapine (as embonate), Olanzapine embonate, Olanzapine pamoate, Olanzapine pamoate anhydrous, Olanzapine pamoate monohydrate, Zypadhera', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.613 | Q15 | When was Sibutramine Hydrochloride approved by the FDA? | The drug Sibutramine Hydrochloride was first FDA approved for use in 1997. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sibutramine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%sibutramine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%sibutramine hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2809', 'drugName': 'Sibutramine Hydrochloride', 'tradeNames_string': 'Meridia', 'drugSynonyms_string': 'BTS 54524, BTS-54524, NSC-758928, Sibutramine hcl, Sibutramine hydrochloride, Sibutramine hydrochloride civ, Sibutramine hydrochloride hydrate, Sibutramine hydrochloride monohydrate', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.183 | Q15 | When was Ritobegron approved by the FDA? | The drug Ritobegron has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ritobegron%" OR LOWER(tradeNames_string) LIKE "%ritobegron%" OR LOWER(drugSynonyms_string) LIKE "%ritobegron%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.305 | Q15 | When was Selegiline Hydrochloride approved by the FDA? | The drug Selegiline Hydrochloride was first FDA approved for use in 1989. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%selegiline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%selegiline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%selegiline hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_991', 'drugName': 'Selegiline Hydrochloride', 'tradeNames_string': 'Centrapryl 10, Centrapryl 5, Eldepryl, Ensam, Selegiline hydrochloride, Stilline 10, Stilline 5, Vivapryl, Zelapar', 'drugSynonyms_string': 'L-deprenyl, NSC-759259, Selegiline hcl, Selegiline hydrochloride', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.502 | Q15 | When was Methotrexate Sodium approved by the FDA? | The drug Methotrexate Sodium was first FDA approved for use in 1953. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methotrexate sodium%" OR LOWER(tradeNames_string) LIKE "%methotrexate sodium%" OR LOWER(drugSynonyms_string) LIKE "%methotrexate sodium%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1736', 'drugName': 'Methotrexate Sodium', 'tradeNames_string': 'Abitrexate, Folex, Folex pfs, Methotrexate lpf, Methotrexate preservative free, Methotrexate sodium, Methotrexate sodium preservative free, Mexate, Mexate-aq, Mexate-aq preserved, Trexall, Xatmep', 'drugSynonyms_string': 'ADX-2191 SODIUM, Disodium methotrexate, Methotrexate (as disodium), Methotrexate disodium, Methotrexate disodium salt, Methotrexate sodium, Methotrexate sodium salt, Methotrexate, sodium salt', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1696 | Q15 | When was Phenylbutazone approved by the FDA? | The drug Phenylbutazone was first FDA approved for use in 1980. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenylbutazone%" OR LOWER(tradeNames_string) LIKE "%phenylbutazone%" OR LOWER(drugSynonyms_string) LIKE "%phenylbutazone%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4421', 'drugName': 'Phenylbutazone', 'tradeNames_string': 'Antadol, Azolid, Butacote, Butaject, Butazolidin, Elmedal, Equiphar, Phenylbutazone, Pro-Bute', 'drugSynonyms_string': 'Ambene, Artrizin, Bizolin, Butadion, Butadiona, Butapirazol, Butatron, Butoz, Buzon, Diphebuzol, Diphenylbutazone, Ecobutazone, Equipalazone, Exrheudon n, Fenibutazona, Fenibutol, Fenylbutazon, Flexazone, G-13871, Intrabutazone, Intrazone, Mepha-butazon, NSC-25134, Phebuzine, Phenylbutazone, Phenyzene, R-3-ZON, Robizone-v, Shigrodin, Tevcodyne, Uzone, Zolaphen', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1721 | Q15 | When was Lazertinib approved by the FDA? | The drug Lazertinib has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lazertinib%" OR LOWER(tradeNames_string) LIKE "%lazertinib%" OR LOWER(drugSynonyms_string) LIKE "%lazertinib%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1662 | Q15 | When was Tenecteplase approved by the FDA? | The drug Tenecteplase was first FDA approved for use in 2000. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tenecteplase%" OR LOWER(tradeNames_string) LIKE "%tenecteplase%" OR LOWER(drugSynonyms_string) LIKE "%tenecteplase%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5412', 'drugName': 'Tenecteplase', 'tradeNames_string': 'Metalyse', 'drugSynonyms_string': 'TNK-TPA, Tenecteplase', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1639 | Q15 | When was At-7519 approved by the FDA? | The drug At-7519 has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%at-7519%" OR LOWER(tradeNames_string) LIKE "%at-7519%" OR LOWER(drugSynonyms_string) LIKE "%at-7519%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.523 | Q15 | When was Rivoceranib approved by the FDA? | The drug Rivoceranib has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rivoceranib%" OR LOWER(tradeNames_string) LIKE "%rivoceranib%" OR LOWER(drugSynonyms_string) LIKE "%rivoceranib%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1985 | Q15 | When was Tebentafusp approved by the FDA? | The drug Tebentafusp was first FDA approved for use in 2022. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tebentafusp%" OR LOWER(tradeNames_string) LIKE "%tebentafusp%" OR LOWER(drugSynonyms_string) LIKE "%tebentafusp%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5977', 'drugName': 'Tebentafusp', 'tradeNames_string': 'Kimmtrak', 'drugSynonyms_string': 'IMCGP-100, IMCGP100, IMCgp 100, IMMTAC IMCGP100, Imcgp100, ImmTAC IMCgpgp 100, Kimmtrak, Tebentafusp, Tebentafusp tebn, Tebentafusp-tebn', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1078 | Q15 | When was Interferon Alfacon-1 approved by the FDA? | The drug Interferon Alfacon-1 was first FDA approved for use in 1997. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%interferon alfacon-1%" OR LOWER(tradeNames_string) LIKE "%interferon alfacon-1%" OR LOWER(drugSynonyms_string) LIKE "%interferon alfacon-1%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4051', 'drugName': 'Interferon Alfacon-1', 'tradeNames_string': 'Infergen', 'drugSynonyms_string': 'Interferon alfacon-1, Rsifn-co', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.482 | Q15 | When was Icatibant Acetate approved by the FDA? | The drug Icatibant Acetate was first FDA approved for use in 2011. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%icatibant acetate%" OR LOWER(tradeNames_string) LIKE "%icatibant acetate%" OR LOWER(drugSynonyms_string) LIKE "%icatibant acetate%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_226', 'drugName': 'Icatibant Acetate', 'tradeNames_string': 'Firazyr', 'drugSynonyms_string': 'HOE 140, HOE-140, Icatibant acetate', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.160 | Q15 | When was Bms-741672 approved by the FDA? | The drug Bms-741672 has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bms-741672%" OR LOWER(tradeNames_string) LIKE "%bms-741672%" OR LOWER(drugSynonyms_string) LIKE "%bms-741672%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1253 | Q15 | When was Prednicarbate approved by the FDA? | The drug Prednicarbate was first FDA approved for use in 1991. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prednicarbate%" OR LOWER(tradeNames_string) LIKE "%prednicarbate%" OR LOWER(drugSynonyms_string) LIKE "%prednicarbate%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3323', 'drugName': 'Prednicarbate', 'tradeNames_string': 'Dermatop, Dermatop e emollient, Prednicarbate', 'drugSynonyms_string': 'HOE 777, HOE-777, LAS-189961, LAS-41003 COMPONENT PREDNICARBATE, LAS189961, NSC-760042, Prednicarbate, S 77 0777, S-77 0777, S-77-0777, S-770777', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1205 | Q15 | When was Vortioxetine approved by the FDA? | The drug Vortioxetine was first FDA approved for use in 2013. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vortioxetine%" OR LOWER(tradeNames_string) LIKE "%vortioxetine%" OR LOWER(drugSynonyms_string) LIKE "%vortioxetine%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2170', 'drugName': 'Vortioxetine', 'tradeNames_string': 'Brintellix', 'drugSynonyms_string': 'LU AA21004, LU-AA21004, LUAA21004, Vortioxetine', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2171', 'drugName': 'Vortioxetine', 'tradeNames_string': 'Brintellix', 'drugSynonyms_string': 'LU AA21004, LU-AA21004, LUAA21004, Vortioxetine', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2172', 'drugName': 'Vortioxetine', 'tradeNames_string': 'Brintellix', 'drugSynonyms_string': 'LU AA21004, LU-AA21004, LUAA21004, Vortioxetine', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_776', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_string': 'Trintellix', 'drugSynonyms_string': 'Lu AA21004 (HBr), Lu aa21004 hbr, Lu-aa21004 hydrobromide, Vortioxetine hydrobromide', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_777', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_string': 'Trintellix', 'drugSynonyms_string': 'Lu AA21004 (HBr), Lu aa21004 hbr, Lu-aa21004 hydrobromide, Vortioxetine hydrobromide', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_778', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_string': 'Trintellix', 'drugSynonyms_string': 'Lu AA21004 (HBr), Lu aa21004 hbr, Lu-aa21004 hydrobromide, Vortioxetine hydrobromide', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.17 | Q15 | When was Insulin Susp Protamine Zinc Beef/Pork approved by the FDA? | The drug Insulin Susp Protamine Zinc Beef/Pork was first FDA approved for use in 1966. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin susp protamine zinc beef/pork%" OR LOWER(tradeNames_string) LIKE "%insulin susp protamine zinc beef/pork%" OR LOWER(drugSynonyms_string) LIKE "%insulin susp protamine zinc beef/pork%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2164', 'drugName': 'Insulin Susp Protamine Zinc Beef/Pork', 'tradeNames_string': 'Protamine zinc & iletin i (beef-pork)', 'drugSynonyms_string': 'Insulin susp protamine zinc beef/pork', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1550 | Q15 | When was Fosphenytoin approved by the FDA? | The drug Fosphenytoin was first FDA approved for use in 1996. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosphenytoin%" OR LOWER(tradeNames_string) LIKE "%fosphenytoin%" OR LOWER(drugSynonyms_string) LIKE "%fosphenytoin%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_993', 'drugName': 'Fosphenytoin', 'tradeNames_string': '', 'drugSynonyms_string': 'Fosphenytoin, Np-06', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_181', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_string': 'Cerebyx, Fosphenytoin sodium, Pro-epanutin, Sesquient', 'drugSynonyms_string': 'ACC-9653-010, ACC-9653-010 (SODIUM SALT), CI 982, CI-982, Fosphenytoin disodium salt, Fosphenytoin sodium', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1081 | Q15 | When was Oxybate approved by the FDA? | The drug Oxybate was first FDA approved for use in 2002. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxybate%" OR LOWER(tradeNames_string) LIKE "%oxybate%" OR LOWER(drugSynonyms_string) LIKE "%oxybate%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4208', 'drugName': 'Sodium Oxybate', 'tradeNames_string': 'Xyrem', 'drugSynonyms_string': '.gamma.-hydroxybutyrate sodium salt, Catabate, Lumryz, NSC-84223, Oxybate sodium, Sodium oxybat, Sodium oxybate, Sodium oxybutyrate, WY-3478', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4894', 'drugName': 'Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': '.gamma.-hydroxybutyrate, Gamma hydroxybutyrate, Gamma-hydroxybutyrate, Oxybate, Xyrem', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2016', 'drugName': 'Magnesium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Magnesium oxybate, Oxybate magnesium', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2097', 'drugName': 'Calcium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Calcium oxybate, Oxybate calcium', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2573', 'drugName': 'Potassium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxybate potassium, Potassium oxybate', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1972 | Q15 | When was Levodopa approved by the FDA? | The drug Levodopa was first FDA approved for use in 1970. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levodopa%" OR LOWER(tradeNames_string) LIKE "%levodopa%" OR LOWER(drugSynonyms_string) LIKE "%levodopa%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4351', 'drugName': 'Levodopa', 'tradeNames_string': 'Bendopa, Brocadopa, Dopar, Inbrija, Larodopa', 'drugSynonyms_string': 'Bendopa, Cvt-301, Levodopa, Levodopum, NSC-118381, V-1512', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.552 | Q15 | When was Dobutamine Hydrochloride approved by the FDA? | The drug Dobutamine Hydrochloride was first FDA approved for use in 1978. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dobutamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dobutamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dobutamine hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2852', 'drugName': 'Dobutamine Hydrochloride', 'tradeNames_string': 'Dobutamine hydrochloride, Dobutrex, Posiject', 'drugSynonyms_string': '46236, Dl-dobutamine hydrochloride, Dobutamine hcl, Dobutamine hydrochloride, NSC-299583', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2853', 'drugName': 'Dobutamine Hydrochloride', 'tradeNames_string': 'Dobutamine hydrochloride, Dobutrex, Posiject', 'drugSynonyms_string': '46236, Dl-dobutamine hydrochloride, Dobutamine hcl, Dobutamine hydrochloride, NSC-299583', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1554 | Q15 | When was Aminophylline approved by the FDA? | The drug Aminophylline was first FDA approved for use in 1940. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aminophylline%" OR LOWER(tradeNames_string) LIKE "%aminophylline%" OR LOWER(drugSynonyms_string) LIKE "%aminophylline%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5470', 'drugName': 'Aminophylline', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5471', 'drugName': 'Aminophylline', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5472', 'drugName': 'Aminophylline', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.665 | Q15 | When was Olsalazine approved by the FDA? | The drug Olsalazine was first FDA approved for use in 1990. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olsalazine%" OR LOWER(tradeNames_string) LIKE "%olsalazine%" OR LOWER(drugSynonyms_string) LIKE "%olsalazine%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4289', 'drugName': 'Olsalazine', 'tradeNames_string': '', 'drugSynonyms_string': 'C. i. mordant yellow 5, Dipentum, Olsalazine', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4290', 'drugName': 'Olsalazine', 'tradeNames_string': '', 'drugSynonyms_string': 'C. i. mordant yellow 5, Dipentum, Olsalazine', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4291', 'drugName': 'Olsalazine', 'tradeNames_string': '', 'drugSynonyms_string': 'C. i. mordant yellow 5, Dipentum, Olsalazine', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3913', 'drugName': 'Olsalazine Sodium', 'tradeNames_string': 'Dipentum', 'drugSynonyms_string': 'Ads, Azodisal sodium, CJ 91B, CJ-91B, Disodium azodisalicylate, Olsalazine disodium salt, Olsalazine sodium, Sodium azodisalicylate, Sodium olsalazine', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3914', 'drugName': 'Olsalazine Sodium', 'tradeNames_string': 'Dipentum', 'drugSynonyms_string': 'Ads, Azodisal sodium, CJ 91B, CJ-91B, Disodium azodisalicylate, Olsalazine disodium salt, Olsalazine sodium, Sodium azodisalicylate, Sodium olsalazine', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3915', 'drugName': 'Olsalazine Sodium', 'tradeNames_string': 'Dipentum', 'drugSynonyms_string': 'Ads, Azodisal sodium, CJ 91B, CJ-91B, Disodium azodisalicylate, Olsalazine disodium salt, Olsalazine sodium, Sodium azodisalicylate, Sodium olsalazine', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1626 | Q15 | When was Pki-179 approved by the FDA? | The drug Pki-179 has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pki-179%" OR LOWER(tradeNames_string) LIKE "%pki-179%" OR LOWER(drugSynonyms_string) LIKE "%pki-179%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1028 | Q15 | When was Amitriptyline Hydrochloride approved by the FDA? | The drug Amitriptyline Hydrochloride was first FDA approved for use in 1961. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amitriptyline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%amitriptyline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%amitriptyline hydrochloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3357', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugSynonyms_string': 'Amitriptyline hcl, Amitriptyline hydrochloride, Amitriptylini hydrochloridum, Etravil, NIH 10794, NSC-104210, Novoprotect, Syneudon', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3358', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugSynonyms_string': 'Amitriptyline hcl, Amitriptyline hydrochloride, Amitriptylini hydrochloridum, Etravil, NIH 10794, NSC-104210, Novoprotect, Syneudon', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1994 | Q15 | When was Gsk-1521498 approved by the FDA? | The drug Gsk-1521498 has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gsk-1521498%" OR LOWER(tradeNames_string) LIKE "%gsk-1521498%" OR LOWER(drugSynonyms_string) LIKE "%gsk-1521498%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1519 | Q15 | When was Intepirdine approved by the FDA? | The drug Intepirdine has not been approved by the FDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%intepirdine%" OR LOWER(tradeNames_string) LIKE "%intepirdine%" OR LOWER(drugSynonyms_string) LIKE "%intepirdine%") AND drugIsApproved = True
LIMIT 100 | [] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.968 | Q15 | When was Dostarlimab approved by the FDA? | The drug Dostarlimab was first FDA approved for use in 2021. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dostarlimab%" OR LOWER(tradeNames_string) LIKE "%dostarlimab%" OR LOWER(drugSynonyms_string) LIKE "%dostarlimab%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6044', 'drugName': 'Dostarlimab', 'tradeNames_string': 'Jemperli', 'drugSynonyms_string': 'Dostarlimab, Dostarlimab gxly, Dostarlimab-gxly, GSK-4057190, GSK4057190, TSR-042, Tsr 042, Tsr-042, WBP-285', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.1883 | Q15 | When was Succinylcholine Chloride approved by the FDA? | The drug Succinylcholine Chloride was first FDA approved for use in 1952. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%succinylcholine chloride%" OR LOWER(tradeNames_string) LIKE "%succinylcholine chloride%" OR LOWER(drugSynonyms_string) LIKE "%succinylcholine chloride%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2723', 'drugName': 'Succinylcholine Chloride', 'tradeNames_string': 'Anectine, Quelicin, Quelicin preservative free, Scoline, Succinylcholine chloride, Sucostrin, Suxamethonium Chloride', 'drugSynonyms_string': 'Choline chloride succinate (2:1), NSC-49132, Succinylcholine chloride, Suxamethone, Suxamethonii chloridum, Suxamethonium chloride, Suxamethonium chloride dihydrate, Suxamethonium chloride hydrate', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q15.287 | Q15 | When was Etoposide Phosphate approved by the FDA? | The drug Etoposide Phosphate was first FDA approved for use in 1996. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etoposide phosphate%" OR LOWER(tradeNames_string) LIKE "%etoposide phosphate%" OR LOWER(drugSynonyms_string) LIKE "%etoposide phosphate%") AND drugIsApproved = True
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2949', 'drugName': 'Etoposide Phosphate', 'tradeNames_string': 'Etopophos, Etopophos preservative free', 'drugSynonyms_string': 'BMY 40481, BMY-40481, Etoposide phosphate, VP-16, VP16, Vepeside', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}] | refined | Distinct, Similarity Search, Multi-Filter | Approval Status |
Q16.664 | Q16 | What Small molecule therapies have been approved by the FDA to treat Transitional Cell Carcinoma? | There are no drug Small molecule therapies approved to treat Transitional Cell Carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "transitional cell carcinoma" OR LOWER(mesh_heading) = "transitional cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1366 | Q16 | What Small molecule therapies have been approved by the FDA to treat nephrolithiasis? | There are no drug Small molecule therapies approved to treat nephrolithiasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nephrolithiasis" OR LOWER(mesh_heading) = "nephrolithiasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.869 | Q16 | What Small molecule therapies have been approved by the FDA to treat cardiac hypertrophy? | There are no drug Small molecule therapies approved to treat cardiac hypertrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cardiac hypertrophy" OR LOWER(mesh_heading) = "cardiac hypertrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.112 | Q16 | What Protein therapies have been approved by the FDA to treat breast neoplasm? | There are no drug Protein therapies approved to treat breast neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "breast neoplasm" OR LOWER(mesh_heading) = "breast neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.334 | Q16 | What Small molecule therapies have been approved by the FDA to treat Adenomyosis? | There are no drug Small molecule therapies approved to treat Adenomyosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adenomyosis" OR LOWER(mesh_heading) = "adenomyosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1013 | Q16 | What Small molecule therapies have been approved by the FDA to treat eating disorder? | There are no drug Small molecule therapies approved to treat eating disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eating disorder" OR LOWER(mesh_heading) = "eating disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1174 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypotension? | There are 2 Small molecule therapy drugs that are approved to treat hypotension which are as follows: Phenylephrine Hydrochloride and Ephedrine Sulfate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypotension" OR LOWER(mesh_heading) = "hypotension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416610', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_416628', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_416646', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_416664', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_416682', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_416700', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418262', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418267', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418272', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418277', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418282', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418287', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418292', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418297', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418302', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418307', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418312', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418317', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418322', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418327', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418332', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418337', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418342', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}, {'UUID': 'DrugTargetsIndication121923_text_418347', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.110 | Q16 | What Protein therapies have been approved by the FDA to treat breast carcinoma? | Goserelin Acetate is the only Protein therapy approved by the FDA to treat breast carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "breast carcinoma" OR LOWER(mesh_heading) = "breast carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096827', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1096841', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1096855', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1096869', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.136 | Q16 | What Protein therapies have been approved by the FDA to treat congenital heart disease? | There are no drug Protein therapies approved to treat congenital heart disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "congenital heart disease" OR LOWER(mesh_heading) = "congenital heart disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1453 | Q16 | What Small molecule therapies have been approved by the FDA to treat pemphigus? | There are 2 Small molecule therapy drugs that are approved to treat pemphigus which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pemphigus" OR LOWER(mesh_heading) = "pemphigus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_217666', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_217854', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_217874', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_218062', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218082', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_218270', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218290', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_218478', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218498', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_218686', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218706', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_218894', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218914', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_219102', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219122', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_219310', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219330', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_219518', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219538', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_219726', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219746', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_219934', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219954', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_220142', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220162', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_220350', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220370', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_220558', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220578', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_220766', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220786', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_226342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_226362', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_226627', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_226647', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_226912', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_226932', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_227197', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_227217', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_227482', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_227502', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_227767', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_227787', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_228052', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228072', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_228337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_228622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228642', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_228907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228927', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_229192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_229212', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_229477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_229497', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_229762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_229782', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_230047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230067', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_230332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230352', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_230617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230637', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_230902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230922', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_231187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_231207', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_231472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_231492', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_231757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_231777', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_232042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_232062', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}, {'UUID': 'DrugTargetsIndication121923_text_232327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_232347', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.204 | Q16 | What Protein therapies have been approved by the FDA to treat lung disease? | There are no drug Protein therapies approved to treat lung disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lung disease" OR LOWER(mesh_heading) = "lung disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.712 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute pancreatitis? | There are no drug Small molecule therapies approved to treat acute pancreatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute pancreatitis" OR LOWER(mesh_heading) = "acute pancreatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.727 | Q16 | What Small molecule therapies have been approved by the FDA to treat albinism? | There are no drug Small molecule therapies approved to treat albinism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "albinism" OR LOWER(mesh_heading) = "albinism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.683 | Q16 | What Small molecule therapies have been approved by the FDA to treat West syndrome? | Ganaxolone is the only Small molecule therapy approved by the FDA to treat West syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "west syndrome" OR LOWER(mesh_heading) = "west syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_945891', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945902', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945913', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945924', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945935', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945946', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945957', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945968', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945979', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_945990', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946001', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946012', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946023', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946034', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946045', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946056', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946067', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946078', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946089', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946100', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946111', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946122', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946133', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946144', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946155', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946166', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946177', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946188', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946199', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946210', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946221', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946232', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946243', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946254', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946265', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946276', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946287', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946298', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946309', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946320', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946331', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946342', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946353', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946364', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946375', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946386', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946397', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946408', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946419', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946430', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946441', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946452', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946463', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946474', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946485', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946496', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946507', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946518', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946529', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946540', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946551', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946562', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946573', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946584', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946595', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946606', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946617', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946628', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946639', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946650', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946661', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946672', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946683', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946694', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946705', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946716', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946727', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946738', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946749', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946760', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946771', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946782', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946793', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946804', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946815', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946826', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946837', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946848', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946859', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946870', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946881', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946892', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946903', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946914', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946925', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946936', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946947', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946958', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946969', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_946980', 'drugName': 'Ganaxolone', 'tradeNames_list': "['Ztalmy']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasms, Infantile', 'efo_term': 'West syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1088 | Q16 | What Small molecule therapies have been approved by the FDA to treat gallbladder cancer? | There are no drug Small molecule therapies approved to treat gallbladder cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gallbladder cancer" OR LOWER(mesh_heading) = "gallbladder cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.436 | Q16 | What Small molecule therapies have been approved by the FDA to treat Fabry disease? | Migalastat Hydrochloride is the only Small molecule therapy approved by the FDA to treat Fabry disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fabry disease" OR LOWER(mesh_heading) = "fabry disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192170', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192171', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192172', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192173', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192174', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192175', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192176', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192177', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192178', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192179', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192180', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192181', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192182', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192183', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192184', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192185', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192186', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192187', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192188', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192189', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192190', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192191', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192192', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192193', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192194', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192195', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192196', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192197', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192198', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192199', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192200', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192201', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192202', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192203', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192204', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192205', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192206', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192207', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192208', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192209', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192210', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192211', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192212', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192213', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192214', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192215', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000102393', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.526 | Q16 | What Small molecule therapies have been approved by the FDA to treat Klinefelter's syndrome? | There are 2 Small molecule therapy drugs that are approved to treat Klinefelter's syndrome which are as follows: Testosterone Undecanoate and Testosterone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "klinefelter's syndrome" OR LOWER(mesh_heading) = "klinefelter's syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921973', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_921986', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_921999', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922012', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922025', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922038', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922051', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922064', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922077', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922090', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922103', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922116', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922129', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922142', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922155', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922168', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922181', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922194', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922207', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922220', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922233', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922246', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922259', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922272', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922285', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922298', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922311', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922324', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922337', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922350', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922363', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922376', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922389', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922402', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922415', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922428', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922441', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922454', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922467', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922480', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922493', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922525', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922561', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922597', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922633', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922669', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922705', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922741', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922777', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922813', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922849', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922885', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922921', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922957', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_922993', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923029', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923065', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923101', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923137', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923173', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923209', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923245', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923281', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923317', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923353', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923389', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923425', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923461', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923497', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923533', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923569', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923605', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923641', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923677', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923713', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923749', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923785', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923821', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923857', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923893', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923929', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_923965', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924001', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924037', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924073', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924109', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924145', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924181', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924217', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924253', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924289', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924325', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}, {'UUID': 'DrugTargetsIndication121923_text_924361', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome"}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.326 | Q16 | What Small molecule therapies have been approved by the FDA to treat Abnormality of blood and blood-forming tissues? | There are no drug Small molecule therapies approved to treat Abnormality of blood and blood-forming tissues. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abnormality of blood and blood-forming tissues" OR LOWER(mesh_heading) = "abnormality of blood and blood-forming tissues") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.66 | Q16 | What Protein therapies have been approved by the FDA to treat Stevens-Johnson syndrome? | There are no drug Protein therapies approved to treat Stevens-Johnson syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stevens-johnson syndrome" OR LOWER(mesh_heading) = "stevens-johnson syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.186 | Q16 | What Protein therapies have been approved by the FDA to treat interstitial cystitis? | There are no drug Protein therapies approved to treat interstitial cystitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "interstitial cystitis" OR LOWER(mesh_heading) = "interstitial cystitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.239 | Q16 | What Protein therapies have been approved by the FDA to treat neutropenia? | There are no drug Protein therapies approved to treat neutropenia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neutropenia" OR LOWER(mesh_heading) = "neutropenia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.915 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic inflammatory demyelinating polyradiculoneuropathy? | There are no drug Small molecule therapies approved to treat chronic inflammatory demyelinating polyradiculoneuropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic inflammatory demyelinating polyradiculoneuropathy" OR LOWER(mesh_heading) = "chronic inflammatory demyelinating polyradiculoneuropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1241 | Q16 | What Small molecule therapies have been approved by the FDA to treat laryngeal squamous cell carcinoma? | There are no drug Small molecule therapies approved to treat laryngeal squamous cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "laryngeal squamous cell carcinoma" OR LOWER(mesh_heading) = "laryngeal squamous cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.870 | Q16 | What Small molecule therapies have been approved by the FDA to treat cardiomyopathy? | There are 2 Small molecule therapy drugs that are approved to treat cardiomyopathy which are as follows: Tafamidis and Tafamidis Meglumine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cardiomyopathy" OR LOWER(mesh_heading) = "cardiomyopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097595', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097599', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097603', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097607', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097611', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097615', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097619', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097624', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097629', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097634', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097639', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.587 | Q16 | What Small molecule therapies have been approved by the FDA to treat Pelvic Inflammatory Disease? | There are no drug Small molecule therapies approved to treat Pelvic Inflammatory Disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pelvic inflammatory disease" OR LOWER(mesh_heading) = "pelvic inflammatory disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1332 | Q16 | What Small molecule therapies have been approved by the FDA to treat morphine dependence? | There are no drug Small molecule therapies approved to treat morphine dependence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "morphine dependence" OR LOWER(mesh_heading) = "morphine dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1049 | Q16 | What Small molecule therapies have been approved by the FDA to treat extranodal nasal NK/T cell lymphoma? | There are no drug Small molecule therapies approved to treat extranodal nasal NK/T cell lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "extranodal nasal nk/t cell lymphoma" OR LOWER(mesh_heading) = "extranodal nasal nk/t cell lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.751 | Q16 | What Small molecule therapies have been approved by the FDA to treat amyloidosis? | There are 2 Small molecule therapy drugs that are approved to treat amyloidosis which are as follows: Tafamidis and Tafamidis Meglumine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "amyloidosis" OR LOWER(mesh_heading) = "amyloidosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097596', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097600', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097604', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097608', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097612', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097616', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097620', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097625', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097630', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097635', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097640', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.347 | Q16 | What Small molecule therapies have been approved by the FDA to treat Arthropathy? | There are no drug Small molecule therapies approved to treat Arthropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "arthropathy" OR LOWER(mesh_heading) = "arthropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1082 | Q16 | What Small molecule therapies have been approved by the FDA to treat food allergy? | There are no drug Small molecule therapies approved to treat food allergy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "food allergy" OR LOWER(mesh_heading) = "food allergy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.486 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hernia? | Bupivacaine is the only Small molecule therapy approved by the FDA to treat Hernia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hernia" OR LOWER(mesh_heading) = "hernia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_662789', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_662857', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_662925', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_662993', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663061', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663129', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663197', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663265', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663333', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663401', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663469', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663537', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663605', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663673', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663741', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663809', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663877', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_663945', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}, {'UUID': 'DrugTargetsIndication121923_text_664013', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1109 | Q16 | What Small molecule therapies have been approved by the FDA to treat glaucoma? | There are 9 Small molecule therapy drugs that are approved to treat glaucoma which are as follows: Epinephrine, Lisdexamfetamine Dimesylate, Clonidine, Brimonidine Tartrate, Latanoprostene Bunod, Latanoprost, Bimatoprost, Travoprost, and Tafluprost. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "glaucoma" OR LOWER(mesh_heading) = "glaucoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360824', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_360877', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_360930', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_360983', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361036', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361089', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361142', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361195', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361248', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361301', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361354', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361407', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361460', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361513', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361566', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361619', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361672', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361725', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361778', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361831', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361884', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361937', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_361990', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362043', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362096', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362149', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362202', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362255', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362308', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362361', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362414', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362467', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362520', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362573', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362626', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362679', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362732', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362785', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362838', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362891', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362944', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_362997', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363050', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363103', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363156', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363209', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363262', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363315', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363368', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363421', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363474', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363527', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363580', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363633', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363686', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363739', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363792', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363845', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363898', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_363951', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364004', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364057', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364110', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364163', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364216', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364269', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364322', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364375', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364428', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364481', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364534', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364587', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364640', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364693', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364746', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364799', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364852', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364905', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_364958', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365011', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365064', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365117', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365170', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365223', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365276', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365329', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365382', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365435', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365488', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365541', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365594', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365647', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365700', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365753', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365806', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365859', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365912', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_365965', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_366018', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_366071', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1635 | Q16 | What Small molecule therapies have been approved by the FDA to treat small cell lung carcinoma? | There are 2 Small molecule therapy drugs that are approved to treat small cell lung carcinoma which are as follows: Trilaciclib Dihydrochloride and Topotecan Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "small cell lung carcinoma" OR LOWER(mesh_heading) = "small cell lung carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_851292', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851293', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851294', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851295', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851296', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851297', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851298', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851299', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851300', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851301', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851302', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851303', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000135446', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851304', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851305', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851306', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851307', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851308', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851309', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851310', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851311', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851312', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851313', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851314', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_851315', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105810', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193573', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193645', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.749 | Q16 | What Small molecule therapies have been approved by the FDA to treat amenorrhea? | Progesterone is the only Small molecule therapy approved by the FDA to treat amenorrhea. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "amenorrhea" OR LOWER(mesh_heading) = "amenorrhea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940055', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amenorrhea', 'efo_term': 'amenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_940099', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amenorrhea', 'efo_term': 'amenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_940143', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amenorrhea', 'efo_term': 'amenorrhea'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.687 | Q16 | What Small molecule therapies have been approved by the FDA to treat Wolff-Parkinson-White Syndrome? | Propranolol Hydrochloride is the only Small molecule therapy approved by the FDA to treat Wolff-Parkinson-White Syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "wolff-parkinson-white syndrome" OR LOWER(mesh_heading) = "wolff-parkinson-white syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937021', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_937044', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_937067', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_937090', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1420 | Q16 | What Small molecule therapies have been approved by the FDA to treat osteogenesis imperfecta? | There are no drug Small molecule therapies approved to treat osteogenesis imperfecta. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteogenesis imperfecta" OR LOWER(mesh_heading) = "osteogenesis imperfecta") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.30 | Q16 | What Protein therapies have been approved by the FDA to treat COVID-19? | There are no drug Protein therapies approved to treat COVID-19. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "covid-19" OR LOWER(mesh_heading) = "covid-19") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.940 | Q16 | What Small molecule therapies have been approved by the FDA to treat colon carcinoma? | There are no drug Small molecule therapies approved to treat colon carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colon carcinoma" OR LOWER(mesh_heading) = "colon carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.169 | Q16 | What Protein therapies have been approved by the FDA to treat hemophagocytic syndrome? | There are no drug Protein therapies approved to treat hemophagocytic syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemophagocytic syndrome" OR LOWER(mesh_heading) = "hemophagocytic syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.789 | Q16 | What Small molecule therapies have been approved by the FDA to treat aseptic meningitis? | There are no drug Small molecule therapies approved to treat aseptic meningitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aseptic meningitis" OR LOWER(mesh_heading) = "aseptic meningitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.705 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute lymphoblastic leukemia? | There are 3 Small molecule therapy drugs that are approved to treat acute lymphoblastic leukemia which are as follows: Dasatinib, Ponatinib Hydrochloride, and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute lymphoblastic leukemia" OR LOWER(mesh_heading) = "acute lymphoblastic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_713206', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713284', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713362', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713440', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713518', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713596', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713674', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713752', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713830', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713908', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713986', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714064', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714142', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714220', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714298', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714376', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714454', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714532', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714610', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714688', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714766', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714844', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714922', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715000', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715078', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715156', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715234', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715312', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715390', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715468', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715546', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715624', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715702', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715780', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715858', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715936', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716014', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716092', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716170', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716248', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716326', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716404', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716482', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716560', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716638', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716716', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716794', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716872', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716950', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717028', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717106', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717184', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717262', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717340', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717418', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717496', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717574', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717652', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717730', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717808', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717886', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717964', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718042', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718120', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718198', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718276', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718354', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718432', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718510', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718588', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718666', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718744', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718822', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718900', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718978', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719056', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719134', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719212', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719290', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719368', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719446', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719524', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719602', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719680', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719758', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719836', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719914', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719992', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720070', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720148', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720226', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720304', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720382', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720460', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720538', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720616', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720694', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720772', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720850', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720928', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1649 | Q16 | What Small molecule therapies have been approved by the FDA to treat spinocerebellar ataxia type 7? | There are no drug Small molecule therapies approved to treat spinocerebellar ataxia type 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinocerebellar ataxia type 7" OR LOWER(mesh_heading) = "spinocerebellar ataxia type 7") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1448 | Q16 | What Small molecule therapies have been approved by the FDA to treat paranasal sinus neoplasm? | There are no drug Small molecule therapies approved to treat paranasal sinus neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "paranasal sinus neoplasm" OR LOWER(mesh_heading) = "paranasal sinus neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.71 | Q16 | What Protein therapies have been approved by the FDA to treat Vitiligo? | There are no drug Protein therapies approved to treat Vitiligo. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vitiligo" OR LOWER(mesh_heading) = "vitiligo") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.